BRD4 has been shown to cluster at super-enhancer regions involved in the control of pivotal oncogenes, such as c-Myc, Bcl-xl, and Bcl-2 [14, 28–30], suggesting that it might be a target providing an alternative strategy to improve outcomes for T-ALL patients. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.